Tuesday, 26 August 2025
CTP has completed an 18,000 sqm build-to-suit production facility for SCHOTT Pharma at CTPark Jagodina in Serbia. The new site expands SCHOTT Pharma’s manufacturing network, which now spans 15 countries, and will focus on the production of glass ampoules used in vaccines and other injectable medications.
The facility will employ 180 people and adds to SCHOTT Pharma’s existing network of ten ampoule production sites worldwide. The building was developed according to CTP’s modern industrial standards, which include sustainability-focused features and energy-efficient infrastructure.
CTPark Jagodina is located near the A1 highway and offers access to key cities including Belgrade and Niš, as well as multiple EU markets through direct road connections. The park is also situated within a region with a population of approximately 400,000 and close to the university city of Kragujevac, providing access to a skilled workforce.
The park includes BREEAM Very Good-certified buildings and features such as rooftop solar panels, water reuse systems, and amenities designed to support employee wellbeing. It spans 22.9 hectares, with 33,000 sqm of space already built and 88,000 sqm planned for future development.
Petar Kolognat, Business Development Director for CTP Serbia, stated that the partnership with SCHOTT Pharma supports the wider industrial network in the region and offers flexibility for future expansion.
Denis Nikitin, Plant Manager at SCHOTT Pharma, noted the suitability of the site and the cooperation with CTP throughout the project, highlighting the location’s industrial relevance and access to qualified personnel.
CTP manages 600,000 sqm of industrial and logistics space in Serbia, with 200,000 sqm of new space expected to be delivered by the end of 2025. The company continues to develop facilities across Serbia’s main cities, including Belgrade, Novi Sad, Kragujevac, and Niš, as demand grows from multinational manufacturers seeking to relocate production closer to European markets.
